Geralgine-P is commonly used for the temporary relief of pain and discomfort associated with a variety of conditions and to help reduce fever.

The medicine is generally applicable across conditions characterized by episodic or fluctuating manifestations, including managing mild to moderate pain from tension headaches, dental procedures, musculoskeletal aches, and menstrual cramps (dysmenorrhea), as well as symptoms of fever and generalized body aches linked to colds or influenza. The medicine is generally used in contexts involving heightened systemic burden where short-term symptomatic assistance is needed.

“The medicine may provide supportive relief that helps ease the overall symptom burden during acute, disruptive episodes.”

The medicine provides support that helps ease the overall symptom burden and may assist with maintaining functional stability when symptoms are more noticeable, and generally contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Acute Symptomatic Discomfort

Geralgine-P is generally applied when symptoms of increased neurological or muscular activity (e.g., headache) co-occur with symptoms related to systemic imbalance (e.g., fever), making it a relevant option for managing combined symptomatic distress in adults.

Official Eligibility and Non-Eligibility Rules

Eligibility for Geralgine-P is determined by governmental regulatory documentation, which specifies both permitted populations and absolute prohibitions based on age, physiological status, and underlying health conditions.

Classification	Status and Constraints (Official Label)
Approved Age Groups	Adults and Adolescents aged 12 years and older
Absolute Contraindication	Children under 12 years
Absolute Contraindication	Known hypersensitivity to Paracetamol, Propyphenazone, Caffeine, or any pyrazolone compounds (e.g., metamizole)
Absolute Contraindication	Severe hepatic insufficiency (Child-Pugh >9) or severe renal insufficiency
Absolute Contraindication	Lactation/Breastfeeding women and pregnancy (particularly first and final six weeks)
Absolute Contraindication	Patients with G6PD deficiency, haemopathies (like granulocytopenia), or acute hepatic porphyria
Conditional Use (Caution)	Patients with mild to moderate hepatic/renal impairment, Gilbert's syndrome, asthma/chronic rhinitis, or the elderly

The medicine is formally contraindicated for patients with severe organ impairment, specific metabolic/blood disorders, and hypersensitivity reactions. Use is restricted to the established user groups of adults and adolescents aged 12 and above. The product must also not be used alongside any other medicine containing Paracetamol.

Geralgine-P contains Acetaminophen (Paracetamol) and Codeine, and its interactions are defined by the profiles of these active components. Care is required when this product is used concurrently with specific medications or substance categories due to the potential for altered effects or increased risk of adverse events.

Drug-Drug Interactions

Interacting Product Category	Potential Effect	Mechanism / Note
Oral Anticoagulants (e.g., Warfarin)	Increased risk of bleeding	Acetaminophen may potentiate the effect of anticoagulants, particularly with prolonged use or at higher doses. Requires closer monitoring of INR (International Normalized Ratio).
Other Acetaminophen/Paracetamol Products	Increased risk of toxicity	Concomitant use with other products containing the same active ingredient is strictly advised against to prevent exceeding the maximum recommended daily dose, which can lead to severe liver toxicity.
CNS Depressants (e.g., Sedatives, Alcohol)	Additive CNS depression	The Codeine component, an opioid, can potentiate the effects of substances that cause central nervous system depression, leading to profound sedation, respiratory depression, or coma.
CYP2D6 or CYP3A4 Inhibitors	Altered Codeine effect	The metabolism of Codeine is mediated by Cytochrome P450 enzymes (primarily CYP2D6 for conversion to active metabolite, and CYP3A4). Inhibitors of these enzymes may increase or decrease Codeine's active metabolite levels, leading to reduced efficacy or increased risk of side effects.

Important Interaction Notes

It is important to inform a healthcare provider of all medicines, including prescription, over-the-counter, and herbal supplements, before using this product. The risk of hepatotoxicity from Acetaminophen is also elevated by chronic, excessive consumption of alcohol.

Geralgine-P is a fixed-dose combination product containing Acetaminophen (Paracetamol) and Caffeine.

Acetaminophen exhibits its primary mechanism of action within the central nervous system (CNS). It functions as an inhibitor of prostaglandin synthesis, likely targeting a centrally-expressed cyclooxygenase (COX) enzyme variant, or potentially COX-2 in an environment with low hydroperoxide tone. This interaction results in the inhibition of Prostaglandin E2 (PGE2) production within the spinal cord and supraspinal structures. An alternative pathway involves its metabolite, N-acylphenolamine (AM404), which acts as an agonist at the Transient Receptor Potential Vanilloid-1 (TRPV1) receptor and inhibits the cellular reuptake of the endocannabinoid anandamide (AEA). Downstream, these central actions modulate descending inhibitory serotonergic pathways and suppress the action of endogenous pyrogens on the hypothalamic heat-regulating center, leading to systemic thermoregulation.

Caffeine acts as a non-selective antagonist at adenosine receptors (A1 and A2A) throughout the CNS and peripheral tissues. By blocking these receptors, it prevents endogenous adenosine from binding, leading to systemic neural excitation and modulation of cerebral vasoconstrictive tone.

How to Use Geralgine-P: Official Administration Guidelines

This section outlines the instructions for the correct administration and dosing of Geralgine-P (Paracetamol 250 mg / Propyphenazone 150 mg / Caffeine 50 mg).

---

Dosing Schedule and Frequency

Patient Group	Single Dose	Maximum Daily Use
Adults	1 to 2 tablets	Up to three single doses within 24 hours
Adolescents (12–16 years)	1 tablet	Up to three single doses within 24 hours

Geralgine-P is intended for intermittent use (as needed) and should not be taken for more than one week (7 days), except under the direction of a healthcare professional. The lowest dose necessary to achieve effect should be used.

---

Administration Method and Special Conditions

Instruction	Detail
Route of Administration	The medicine is for oral (by mouth) ingestion only.
Intake Instructions	Tablets should be swallowed whole with ample water or other fluid.
Use in Organ Impairment	Caution is required for patients with severe renal failure, and dose adjustment may be necessary. The medicine is contraindicated in severe hepatic insufficiency.

---

Procedural Structure

The approved protocol requires the patient to take the specified number of tablets with fluid. The key limitation governing the medication’s use is the maximum frequency; a new single dose must not be taken if the limit of three doses in 24 hours would be exceeded. These official constraints define the medication as a short-term, symptom-based treatment.

Research Evidence / Overview of Studies for Geralgine-P

Evidence for Use in Acute Headache Pain

Research exploring this combination was studied for acute episodic tension-type headache and migraine. Clinical studies monitored outcomes related to physical discomfort, such as the time needed to report perceptible relief and measures of symptom intensity change over defined short time intervals. This research primarily involved randomized controlled trials (RCTs) and systematic reviews.

Reports from these studies include measurements of changes measured during the study period, helping contextualize how patients reported their experience during these acute episodes.

However, certainty remains low in some areas because certain early trials examining this usage experienced difficulties, and findings varied across some studies. Furthermore, evidence is limited for the triple-ingredient combination in all headache contexts, and long-term effects for repeated use are not fully established.

Evidence for Acute General Pain Relief

The combination was studied for acute, short-term pain, often examined using models like post-dental surgical pain (dentoalveolar pain). Research examined outcomes related to physical discomfort and time-sensitive measures of symptom reduction over the first few hours after a single dose.

Data show patterns related to measured changes in outcomes related to physical discomfort over a four-hour window, as well as patient-reported outcomes describing perceived discomfort. The evidence was derived from studies modeling acute, short-term pain and involved pooled data from several RCTs.

While research provides insight into short-term changes, the follow-up durations were limited. This means there is limited information for long-term outcomes, and these results apply only to the specific acute, single-dose pain populations studied.

Research Gaps and Unanswered Questions

A key limitation across the evidence base is that follow-up durations were limited, focusing on acute changes rather than long-term effects. This means that the long-term clinical profile, including any potential changes in outcomes reflecting daily functioning, is not fully established. Additionally, comparative evidence is lacking for the triple combination versus a wide range of other widely used options for general pain. Research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Key Studies & References

1. A risk-benefit assessment of paracetamol (acetaminophen) combined with caffeine

Common questions about Geralgine-P (FAQ)

---

Q: How quickly does Geralgine-P usually start working?

Clinical studies examining the combination of ingredients in Geralgine-P for acute pain indicate a fast onset of action. Some research reports relief may be felt as early as 15 minutes following use.

Q: How long do the effects of Geralgine-P last?

Studies conducted on this product to measure its effectiveness in acute pain models typically monitor and measure changes in discomfort over a four-hour interval following a single dose. This indicates the general duration of effect the medicine is designed to provide.

Q: Can Geralgine-P be used long-term?

Official guidance indicates that the medicine is for intermittent use and is typically limited to no longer than one week (7 days). This is because prolonged use carries specific risks, and it should only be continued under the direction of a healthcare professional.

Q: Can Geralgine-P interact with common vitamins or supplements?

While specific major interactions are listed for certain drug classes, regulatory documents also advise informing a healthcare provider of all medicines and supplements you are taking, including over-the-counter and herbal products. This information allows for a complete safety review by a healthcare provider.

Q: Is Geralgine-P safe to use during pregnancy?

Official labeling indicates that the use of Geralgine-P is generally advised against during pregnancy due to potential risks. This includes a possible increased risk associated with the caffeine component of the medicine.

Q: Why do some people say Geralgine-P is hard to find?

The ingredient Propyphenazone, a component of Geralgine-P, is a pyrazolone derivative whose regulatory status varies globally. This specific ingredient has been restricted or banned in some countries due to regulatory factors related to the pyrazolone class of ingredients, which can affect the product's availability.

Q: What kind of studies support the use of Geralgine-P?

The medicine's official use is supported by clinical research, primarily including randomized controlled trials (RCTs). These studies examine outcomes like the time required for symptom relief in conditions such as acute pain and headache.

Q: Is Geralgine-P considered a painkiller or something else?

Regulatory classifications describe this type of medicine as an analgesic (a pain reliever) and an antipyretic (a fever reducer). It is officially described as an analgesic and antipyretic combination.

Q: Is Geralgine-P a prescription-only medicine?

The legal availability of this type of medicine is subject to local regulatory classification. In some regions, this medicine is available as an over-the-counter (OTC) preparation, while in others, it may require a prescription.

Q: Are there any warnings about driving while taking Geralgine-P?

Official documents contain a warning that the medicine may cause effects such as dizziness, sleepiness, drowsiness, or fatigue. Official documents list warnings regarding tasks requiring alertness, such as driving or operating machinery, if these effects are experienced.

Q: Does Geralgine-P have a generic equivalent?

The active ingredients—Paracetamol, Propyphenazone, and Caffeine—are available in several fixed-dose combination products. These are marketed under various brand names globally, though a direct, universally named generic equivalent may not exist.

Q: Is it required to take Geralgine-P with food?

The medicine can be taken with or without food as directed. Regulatory information notes that if stomach upset is experienced, taking the tablets with food or milk may be considered.

Q: Can Geralgine-P be crushed or split?

Regulatory guidance states that tablets should be swallowed whole with fluid. It generally advises against crushing, chewing, or breaking them to ensure proper administration.

Q: Is Geralgine-P safe to take with other pain relievers?

Regulatory documents strictly advise against taking Geralgine-P with any other products containing paracetamol due to the high risk of liver toxicity. Caution is also noted regarding the concurrent use of the medicine with other analgesic classes.

Q: Is Geralgine-P the same as regular Geralgine?

Geralgine-P is a brand name for a fixed-dose combination of active ingredients including Propyphenazone. Its composition is different from other products marketed under similar names, which may contain different analgesic components, such as Codeine.

Q: Can Geralgine-P upset your stomach?

Yes, official documentation lists effects such as Nausea, Indigestion, and Stomach pain as common adverse reactions associated with the use of this medicine.

Q: Are there any serious side effects I should know about?

Serious adverse reactions listed in regulatory documents include the risk of severe hepatic (liver) damage from exceeding the maximum dose. Other serious but rare events include acute renal failure (kidney damage) and anaphylaxis (a severe allergic reaction).

Q: Does Geralgine-P affect my mood or mental state?

Official documents list adverse effects related to the nervous system, potentially affecting mental state, due to the caffeine component. These include the listing of restlessness, nervousness, anxiety, irritability, and excitability.

Q: Is Geralgine-P the right choice for chronic conditions?

No. The medicine is officially indicated for the relief of acute, mild to moderate pain and is explicitly intended for intermittent, short-term use. Warnings are provided against prolonged or frequent use for chronic conditions.

Q: Can Geralgine-P be used to treat migraines?

Official therapeutic indications for this combination product include the relief of various types of pain. These indications often include migraine, as well as general headache, toothache, and fever.

Q: Is Geralgine-P similar to ibuprofen or acetaminophen?

Geralgine-P contains both Paracetamol (Acetaminophen) and Propyphenazone. Propyphenazone is classified as a non-steroidal anti-inflammatory drug (NSAID), which is the same class that includes ibuprofen.

Q: Can Geralgine-P cause skin reactions or a rash?

Yes, official documents list hypersensitivity reactions, including skin rash, as possible adverse effects associated with the medicine.

Q: Are there any specific foods that interact with Geralgine-P?

The primary interaction concern is the avoidance of excessive intake of caffeine from dietary sources (e.g., coffee, energy drinks, tea) to prevent increasing the risk of caffeine-related side effects. Alcohol is also strongly advised against during treatment.

Q: Is the research for Geralgine-P based on long-term studies?

Research evidence for this combination primarily consists of studies with limited follow-up durations. The focus of the available research has been on achieving short-term relief in acute pain settings rather than establishing long-term outcomes.

Q: Is Geralgine-P a controlled substance?

The active ingredients—Paracetamol, Propyphenazone, and Caffeine—are not typically classified as controlled substances in major regulatory systems. Propyphenazone is classified as a Pyrazolone analgesic.

Q: How does Geralgine-P get processed by the body?

The active ingredients are absorbed and processed (metabolized) by the body primarily in the liver. This processing involves chemical pathways like glucuronidation and sulfation, with the active drugs and their breakdown products then being eliminated from the body.

How to Store and Dispose of Geralgine-P?

To ensure product stability and safety, Geralgine-P (Paracetamol, Propyphenazone, and Caffeine) must be stored according to official regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Store below 30°C (86°F) in a cool and dry place.
Protection	Keep in the original package to protect the tablets from light and moisture.
Handling	Do not freeze. Tablets must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Geralgine-P must be handled as pharmaceutical waste. Official instructions require disposal according to local government regulations, which typically means returning it to a pharmacy or designated collection site. The medicine must not be discarded through household wastewater or standard household trash.